| Stein, Eytan |
| Active, not recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals, Syros Pharmaceuticals, Inc. | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
NCT05024994: A Study of E7820 in People With Bone Marrow (Myeloid) Cancers |
|
|
| Active, not recruiting | 2 | 12 | US | E7820 | Memorial Sloan Kettering Cancer Center, Eisai Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 08/25 | 08/25 | | |
NCT05030441: Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 |
|
|
| Recruiting | 2 | 20 | US | Ivosidenib, TIBSOVO | Washington University School of Medicine, Servier Hellas Pharmaceuticals Ltd., Gateway for Cancer Research | Clonal Cytopenia of Undetermined Significance | 01/30 | 01/30 | | |
| Terminated | 1/2 | 24 | Europe, US | Lanraplenib, LANRA, Gilteritinib, XOSPATA® | Kronos Bio, Kronos Bio, Inc. | Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 04/24 | 04/24 | | |
NCT04243785: A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
|
|
| Recruiting | 1 | 80 | US | BTX-A51, Azacitidine | Edgewood Oncology Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 03/26 | 03/27 | | |
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome |
|
|
| Completed | 1 | 55 | US, RoW | CB-5339, CB-5339 Tosylate | Cleave Therapeutics, Inc. | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | 07/23 | 07/23 | | |
NCT05144334: A Study of BTX-1188 in Subjects With Advanced Malignancies |
|
|
| Terminated | 1 | 8 | US | BTX-1188 | BioTheryX, Inc. | Advanced Solid Tumor, Non Hodgkin Lymphoma, Acute Myeloid Leukemia | 09/23 | 09/23 | | |
NCT06146257: A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes |
|
|
| Recruiting | 1 | 48 | US | GLB-001, GLB-C183-A-2 | GluBio Therapeutics Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 10/25 | 10/26 | | |
| Recruiting | 1 | 100 | US | REM-422 | Remix Therapeutics | Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory | 03/26 | 06/27 | | |
KT253-AL-101, NCT05775406: Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors |
|
|
| Completed | 1 | 52 | US | KT-253 | Kymera Therapeutics, Inc. | Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05756777: A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 1 | 36 | US | Gilteritinib, Ivosidenib, Enasidenib | Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc. | Acute Myeloid Leukemia (AML) | 02/25 | 02/25 | | |
| Recruiting | 1 | 144 | US | FHD-286, Low Dose Cytarabine, LDAC, Decitabine | Foghorn Therapeutics Inc. | Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | 09/25 | 06/27 | | |
| Recruiting | 1 | 50 | US | SGR-2921 | Schrödinger, Inc. | Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes | 12/25 | 12/25 | | |
| Available | N/A | | US | Revumenib, SNDX-5613 | Syndax Pharmaceuticals | Relapsed/Refractory Acute Leukemia | | | | |
| Bolton, Kelly |
NCT06240754: Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial |
|
|
| Recruiting | 2 | 15 | US | Enasidenib | Washington University School of Medicine, Bristol-Myers Squibb, Damon Runyon Cancer Research Foundation | Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance | 09/26 | 10/26 | | |
NCT05030441: Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 |
|
|
| Recruiting | 2 | 20 | US | Ivosidenib, TIBSOVO | Washington University School of Medicine, Servier Hellas Pharmaceuticals Ltd., Gateway for Cancer Research | Clonal Cytopenia of Undetermined Significance | 01/30 | 01/30 | | |
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Recruiting | 1 | 49 | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease | 09/26 | 12/26 | | |
